Open AccessEuglycemic ketoacidosis complicating empagliflozin therapy in a Bangladeshi type 2 diabetic lady
Author(s) -
Rezwana Laboni,
Faria Afsana,
Kazi Nazmul Hossain,
Rushda Sharmin Binte Rouf,
Mohammod Feroz Amin,
SM Ashrafuzzaman,
Md Faruque Pathan
Publication year - 2021
Publication title -
birdem medical journal
Language(s) - English
Resource type - Journals
eISSN - 2305-3720
pISSN - 2305-3712
DOI - 10.3329/birdem.v11i3.55229
Subject(s) - empagliflozin , diabetic ketoacidosis , medicine , metabolic acidosis , ketoacidosis , acidosis , diabetes mellitus , complication , endocrinology , type 2 diabetes , type 1 diabetes , bicarbonate , ketone bodies , metabolic disorder , gastroenterology , metabolism
Diabetic ketoacidosis (DKA) is an acute complication of diabetes mellitus, which may occurin both type 1 and type 2 diabetic patients. It is characterized by hyperglycaemia [blood glucose levels > 250 mg/dL (13.8 mmol/ L)], metabolic acidosis (pH <7.3 or serum bicarbonate <15 mmol/L) with an increased anion gap and the presence of ketone bodies in blood or urine. A subgroup of patients may present without signs of hyperglycemia, rather present with euglycemia, posing a diagnostic challenge due to the absence of the cardinal findings of the pathophysiology in DKA. Here, we report a case of euglycemic ketoacidosis complicating a 50-year-old Bangladeshi diabetic lady receiving empagliflozin treatment.BIRDEM Med J 2021; 11(3): 243-245
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom